Back to User profile » Dr James Sterchele
Paper published by Dr James Sterchele:
Original Research
Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
Kongnakorn T, Sterchele JA, Salvador CG, Getsios D, Mwamburi M
ClinicoEconomics and Outcomes Research 2014, 6:141-149
Published Date: 1 April 2014